Clinical Trial Update: Autologous Stem Cell Transplant (ASCT) With Intravenous Busulfan and Melphalan as Conditioning Regimen [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating autologous stem cell transplantation using intravenous busulfan and melphalan as conditioning for multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• BUSULFAN (Busulfan)
• Melphalan (Melphalan)

Snippet

Sponsor: Fundacion Para La Investigacion Hospital La Fe | Conditions: Multiple Myeloma | Phase 2 | Status: UNKNOWN